Orexigen Therapeutics

Orexigen Therapeutics, Inc.
Public
Founded 2002 (2002)
Founder Eckard Weber
Headquarters La Jolla, California, U.S.
Website www.orexigen.com

Orexigen Therapeutics is a public American pharmaceutical company focused on development of treatments for obesity.[1] The company is based in La Jolla, California and was established by Eckard Weber in 2002.[1] As a public company, Orexigen is traded on the NASDAQ exchange under the stock symbol OREX.[1] The company has a single product, Contrave, approved for use in the United States in 2014.[2] The launch of Contrave was conducted through a sales force of 900.[3] Observation of the market performance of Qsymia and Belviq suggest overall low demand for pharmaceutical obesity therapies, calling into question earnings potential for Orexigen's offering.[2]

References

  1. 1 2 3 "OREX Key Statistics". MarketWatch. Retrieved 12 September 2014.
  2. 1 2 Osborne, Spencer (7 October 2014). "Orexigen On A Tear - In The Wrong Direction". Seeking Alpha.
  3. ↑ Osborne, Spencer (12 December 2014). "Contrave Sales Continue To Impress". Seeking Alpha.


This article is issued from Wikipedia - version of the 10/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.